AU2017285726B2 - Methods for diagnosing and treating metastatic cancer - Google Patents

Methods for diagnosing and treating metastatic cancer Download PDF

Info

Publication number
AU2017285726B2
AU2017285726B2 AU2017285726A AU2017285726A AU2017285726B2 AU 2017285726 B2 AU2017285726 B2 AU 2017285726B2 AU 2017285726 A AU2017285726 A AU 2017285726A AU 2017285726 A AU2017285726 A AU 2017285726A AU 2017285726 B2 AU2017285726 B2 AU 2017285726B2
Authority
AU
Australia
Prior art keywords
c14orf142
cancer
mirna
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017285726A
Other languages
English (en)
Other versions
AU2017285726A1 (en
Inventor
John Lewis
Konstantin Stoletov
Lian Willetts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entos Pharmaceuticals Inc
Original Assignee
Entos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entos Pharmaceuticals Inc filed Critical Entos Pharmaceuticals Inc
Publication of AU2017285726A1 publication Critical patent/AU2017285726A1/en
Application granted granted Critical
Publication of AU2017285726B2 publication Critical patent/AU2017285726B2/en
Priority to AU2023203737A priority Critical patent/AU2023203737B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017285726A 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer Active AU2017285726B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023203737A AU2023203737B2 (en) 2016-06-14 2023-06-15 Methods for diagnosing and treating metastatic cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer
CA2,932,910 2016-06-14
PCT/CA2017/050729 WO2017214726A1 (en) 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203737A Division AU2023203737B2 (en) 2016-06-14 2023-06-15 Methods for diagnosing and treating metastatic cancer

Publications (2)

Publication Number Publication Date
AU2017285726A1 AU2017285726A1 (en) 2019-01-24
AU2017285726B2 true AU2017285726B2 (en) 2023-03-16

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017285726A Active AU2017285726B2 (en) 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer
AU2023203737A Active AU2023203737B2 (en) 2016-06-14 2023-06-15 Methods for diagnosing and treating metastatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023203737A Active AU2023203737B2 (en) 2016-06-14 2023-06-15 Methods for diagnosing and treating metastatic cancer

Country Status (8)

Country Link
US (2) US11236331B2 (https=)
EP (1) EP3468564A4 (https=)
JP (2) JP7306829B2 (https=)
CN (1) CN109562121A (https=)
AU (2) AU2017285726B2 (https=)
CA (2) CA2932910A1 (https=)
MX (2) MX2018015474A (https=)
WO (1) WO2017214726A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304988B2 (en) * 2018-01-24 2022-04-19 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098797A2 (en) * 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
KR101446626B1 (ko) 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US20160025728A1 (en) 2013-03-15 2016-01-28 Board Of Regents, The University Of Texas System Brain-specific gene signature of tumor cells
JP6663149B2 (ja) 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098797A2 (en) * 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAODONG HUANG, FANG LIU, CHANGLAI ZHU, JING CAI, HUA WANG, XINXIU WANG, SONG HE, CHENG LIU, LI YAO, ZONGMEI DING, YIXIN ZHANG, TI: "Suppression of KIF3B Expression Inhibits Human Hepatocellular Carcinoma Proliferation", DIGESTIVE DISEASES AND SCIENCES., SPRINGER NEW YORK LLC, US, vol. 59, no. 4, 1 April 2014 (2014-04-01), US , pages 795 - 806, XP055447713, ISSN: 0163-2116, DOI: 10.1007/s10620-013-2969-2 *

Also Published As

Publication number Publication date
WO2017214726A1 (en) 2017-12-21
JP7306829B2 (ja) 2023-07-11
JP2023123748A (ja) 2023-09-05
AU2017285726A1 (en) 2019-01-24
US11236331B2 (en) 2022-02-01
US12421514B2 (en) 2025-09-23
EP3468564A4 (en) 2020-07-29
AU2023203737B2 (en) 2024-08-29
CA2932910A1 (en) 2017-12-14
MX2018015474A (es) 2019-06-06
US20190177727A1 (en) 2019-06-13
EP3468564A1 (en) 2019-04-17
JP2019525903A (ja) 2019-09-12
CN109562121A (zh) 2019-04-02
CA3027430A1 (en) 2017-12-21
US20220112498A1 (en) 2022-04-14
AU2023203737A1 (en) 2023-07-06
MX2022012073A (es) 2022-10-18

Similar Documents

Publication Publication Date Title
AU2023203737B2 (en) Methods for diagnosing and treating metastatic cancer
US12060619B2 (en) Treatment of angiogenesis disorders
CA2692155A1 (en) Compositions comprising human egfr-sirna and methods of use
JP6683986B2 (ja) がん幹細胞分子マーカー
JP5395246B2 (ja) 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット
US20110027297A1 (en) Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing
WO2009084668A1 (ja) 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
US8486905B2 (en) Use of FLJ25416 gene
KR102727594B1 (ko) 육종의 진단 및 치료를 위한 tjp1의 용도
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
US9574240B2 (en) Gene amplification of coactivator CoAA and uses thereof
US20250340946A1 (en) Method of prognosing and treating glioma
DK2257299T3 (en) Modulation of SRPX2-mediated angiogenesis
WO2014095916A1 (en) Ninjurin-1 as therapeutic target for brain tumor
CN115068614A (zh) 用于诊断、治疗和预防癌症的方法和组合物
KR101062167B1 (ko) Ｋｉｒ2.2 억제제를 포함하는 암 치료용 조성물
KR20200118931A (ko) 저산소 환경에서 유발되는 암의 전이 억제용 조성물
CN101407810A (zh) 中期因子基因为靶的小干扰rna、载体及其应用
HK1218868A1 (zh) 用作治疗癌症的疗法的靶标的falz
HK1218868B (en) Falz for use as a target for therapies to treat cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)